ClinicalTrials.gg
CompletedNCT03452917SNOCATUpdated May 24, 2023Results posted

Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest

A Phase 2/3 interventional study of Placebo and sodium nitrite 45 mg in Out-Of-Hospital Cardiac Arrest, sponsored by University of Washington. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by University of Washington · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,502
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Out-of-Hospital Cardiac Arrest with a site in United States — 11 open to participants now, 15 under way, 1 of them phase 3. Out-of-Hospital Cardiac Arrest · United States.

Enrollment
8th of 27
1,502 · median 340
Started
2018
the only one that year
Phase 2/3
2 of 37
none open now
Registered
17th of 37
by date
Lead sponsor
6 of 37
University of Washington

Among the 37 studies in Out-of-Hospital Cardiac Arrest with a site in United States, this one is the 8th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 2/3, and was the 17th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

11 of the 37 studies in Out-of-Hospital Cardiac Arrest with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Out-of-Hospital Cardiac Arrest with a site in United States, or all of them as a file.
02

Study summary

In this clinical study, a total of 1500 patients with out-of-hospital cardiac arrest in Seattle/King County will be enrolled. This will be a randomized clinical trial and patients will receive either two different doses of IV sodium nitrite (45 mg or 60 mg) or placebo during resuscitation in the field by paramedics. The primary outcome will be proportion of patients surviving to hospital admission.

Read the detailed description

The hemodynamic effects of the optimal dose of IV nitrite administered in patients with cardiac arrest are unknown. A significant negative hemodynamic effect from nitrite would decrease the proportion of patients admitted to the hospital, increase rate of re-arrest, or increase the need for vasopressor support in the field. In Seattle/King County, typically 40% of out-of-hospital cardiac arrest patients attended to by paramedics have Return of spontaneous circulation (ROSC) and are admitted to the hospital. In this study, 1500 patients with out-of-hospital cardiac arrest who are undergoing resuscitation by paramedics will be randomized to receive placebo (n=500) or 45 mg IV (n=500) or 60 mg dose (n=500) of sodium nitrite. The study will have 80% power to detect an absolute increase in hospital admission rate of 8% (1-sided .05 level test for each of the two comparisons (45 mg vs placebo and 60 mg vs placebo, no adjustment for multiple comparisons), with a hospital admission rate of 40% in the placebo group and with one interim analysis and stopping only for potential futility and/or harm). The investigators will examine the proportion of patients who survive to discharge as a secondary measure of efficacy.

Patients will be eligible for this study if:

  1. Intravenous access (IV)/intraosseous access(IO)
  2. Cardiac arrest, either Ventricular Fibrillation (VF) or non-VF patients receiving Advanced Cardiac Life Support (ACLS) by Seattle/King County paramedics.
  3. Age 18 years or older
  4. Comatose

Exclusion Criteria

  1. Traumatic cause of cardiac arrest
  2. Prisoner, pregnancy, age less than 18 (special population/vulnerable population)
  3. Known DNAR
  4. Drowning as cause of arrest.
03

Conditions studied

  • Out-Of-Hospital Cardiac Arrest
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiac arrest, either VF or non-VF, patients receiving ACLS by paramedics
  • IV or IO access
  • Comatose

Exclusion criteria

Exclusion Criteria:

  • traumatic cause of cardiac arrest
  • prisoner, pregnancy
  • known DNAR
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,502 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    2 ml of normal saline (n=500)

    Drug: Placebo

  • Experimental
    sodium nitrite

    45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.

    Drug: sodium nitrite 45 mg · Drug: sodium nitrite 60 mg

Interventions

  • DrugPlacebo

    500 patients will 2 ml of normal saline

  • 500 patients will receive 45 mg IV sodium nitrite

  • 500 patients will receive a dose of 60 mg IV sodium nitrite

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Survived to Hospital Admission

    Patient has sustained pulse at arrival to the emergency department

    Time frame: within 24 hours after out of hospital cardiac arrest

Secondary outcomes

  1. Survival to Discharge

    Patient alive at time of discharge from hospital

    Time frame: within 3-6 months after cardiac arrest

  2. Number of Days in ICU

    Number of days the patient is admitted to the Intensive Care Unit

    Time frame: Within first 3 months of hospital admission

  3. Survival to 24 Hours

    Patient is alive after the first 24 hours after admission to the hospital

    Time frame: within first 24 h after hospital admission

  4. Re-arrest

    Patient loses pulses during transport to the hospital. Event occurs before admission to hospital.

    Time frame: before hospital arrival

  5. Survival to 48 Hours After Admission to Hospital

    Patient is alive after first 48 hours after admission to the hospital

    Time frame: within first 48 hours after admission to hospital

  6. Survival to 72 Hours After Admission to Hospital

    Patient is alive after first 72 hours after admission to the hospital

    Time frame: within first 72 hours after admission to hospital

07

Results

Posted May 24, 2023

Participant flow

A total of 1502 were enrolled. A total of 1497 were randomized. 5 patients were excluded due to missing kit information.

Participant flow — Overall Study
MilestonePlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Started499500498
Completed499500498
Not completed000

Outcome measures

PrimaryNumber of Participants Who Survived to Hospital Admission

Patient has sustained pulse at arrival to the emergency department

Time frame:
within 24 hours after out of hospital cardiac arrest
Reported as:
Count of participants · Participants
Number of Participants Who Survived to Hospital Admission
ParticipantsPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Number of Participants Who Survived to Hospital Admission218205212
Statistical analysis
  • Placebo vs Sodium Nitrite 45 mg · Chi-squared · p = 0.82 · Mean difference (final values): -2.9
  • Placebo vs Sodium Nitrite 60 mg · Chi-squared · p = 0.66 · Mean difference (final values): -1.3
SecondarySurvival to Discharge

Patient alive at time of discharge from hospital

Time frame:
within 3-6 months after cardiac arrest
Reported as:
Count of participants · Participants
Survival to Discharge
ParticipantsPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Survival to Discharge746672
Statistical analysis
  • Placebo vs Sodium Nitrite 45 mg · Chi-squared · p = 0.44 · Mean difference (final values): -1.7 · 95% CI -6.0 to 2.6
  • Placebo vs Sodium Nitrite 60 mg · Chi-squared · p = 0.85 · Mean difference (final values): -0.4 · 95% CI -4.9 to 4.0
SecondaryNumber of Days in ICU

Number of days the patient is admitted to the Intensive Care Unit

Time frame:
Within first 3 months of hospital admission
Reported as:
Mean · days
Number of Days in ICU
daysPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Number of Days in ICU6.7 ± 8.18.9 ± 10.47.3 ± 7.2
Statistical analysis
  • Placebo vs Sodium Nitrite 45 mg · Wilcoxon (Mann-Whitney) · p = 0.12 · Mean difference (final values): 2.2 · 95% CI -0.9 to 5.4
  • Placebo vs Sodium Nitrite 60 mg · Wilcoxon (Mann-Whitney) · p = 0.41 · Mean difference (final values): 0.5 · 95% CI -2.5 to 3.6
SecondarySurvival to 24 Hours

Patient is alive after the first 24 hours after admission to the hospital

Time frame:
within first 24 h after hospital admission
Reported as:
Count of participants · Participants
Survival to 24 Hours
ParticipantsPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Survival to 24 Hours181170171
Statistical analysis
  • Placebo vs Sodium Nitrite 45 mg · Chi-squared · p = 0.42 · Mean difference (final values): -2.4 · 95% CI -8.3 to 3.5
  • Placebo vs Sodium Nitrite 60 mg · Chi-squared · p = 0.49 · Mean difference (final values): -2.1 · 95% CI -8.0 to 3.9
SecondaryRe-arrest

Patient loses pulses during transport to the hospital. Event occurs before admission to hospital.

Time frame:
before hospital arrival
Reported as:
Count of participants · Participants
Re-arrest
ParticipantsPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Re-arrest139130156
Statistical analysis
  • Placebo vs Sodium Nitrite 45 mg · Chi-squared · p = 0.93 · Mean difference (final values): 0.4 · 95% CI -7.8 to 8.6
  • Placebo vs Sodium Nitrite 60 mg · Chi-squared · p = 0.20 · Mean difference (final values): 5.3 · 95% CI -2.8 to 13.3
SecondarySurvival to 48 Hours After Admission to Hospital

Patient is alive after first 48 hours after admission to the hospital

Time frame:
within first 48 hours after admission to hospital
Reported as:
Count of participants · Participants
Survival to 48 Hours After Admission to Hospital
ParticipantsPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Survival to 48 Hours After Admission to Hospital161152151
Statistical analysis
  • Placebo vs Sodium Nitrite 45 mg · Chi-squared · p = 0.50 · Mean difference (final values): -2.0 · 95% CI -7.7 to 3.8
  • Placebo vs Sodium Nitrite 60 mg · Chi-squared · p = 0.48 · Mean difference (final values): -2.1 · 95% CI -7.8 to 3.7
SecondarySurvival to 72 Hours After Admission to Hospital

Patient is alive after first 72 hours after admission to the hospital

Time frame:
within first 72 hours after admission to hospital
Reported as:
Count of participants · Participants
Survival to 72 Hours After Admission to Hospital
ParticipantsPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Survival to 72 Hours After Admission to Hospital142133131
Statistical analysis
  • Placebo vs Sodium Nitrite 45 mg · Chi-squared · p = 0.49 · Mean difference (final values): -1.7 · 95% CI -6.0 to 2.6
  • Placebo · Chi-squared · p = 0.85 · Mean difference (final values): -0.4 · 95% CI -4.9 to 4.0

Adverse events

Collected over Adverse events were collected from time period of randomization to hospital discharge. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo422/496 (85.1%)280/496 (56.5%)21/496 (4.2%)
Sodium Nitrite 45 mg433/499 (86.8%)249/499 (49.9%)19/499 (3.8%)
Sodium Nitrite 60 mg425/497 (85.5%)268/497 (53.9%)15/497 (3%)
Most frequent serious events
Most frequent serious events
EventPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Pressors in first 24 hours after hospitalizationCardiac disorders190/496173/499185/497
Re-arrest first 24 hours of hospitalizationCardiac disorders76/49665/49974/497
sustained hypotension in hospital, first 24 hoursCardiac disorders14/49611/4999/497
Most frequent other events
Most frequent other events
EventPlaceboSodium Nitrite 45 mgSodium Nitrite 60 mg
Positive troponinCardiac disorders21/49619/49915/497

Baseline characteristics

5 patients were excluded since they were incarcerated or were less than 18 years of age. We were not allowed to use their data. There were 1492 patients available for analysis.

Age, Categorical
Age, Categorical(Participants)PlaceboSodium Nitrite 45 mgSodium Nitrite 60 mgTotal
<=18 years0101
Between 18 and 65 years222242254718
>=65 years274256243773
Age, Continuous
Age, Continuous(years)PlaceboSodium Nitrite 45 mgSodium Nitrite 60 mgTotal
Median67 (55 to 76)65 (56 to 76)64 (52 to 76)65 (55 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSodium Nitrite 45 mgSodium Nitrite 60 mgTotal
Female165170167502
Male331329330990
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboSodium Nitrite 45 mgSodium Nitrite 60 mgTotal
Hispanic or Latino12141036
Not Hispanic or Latino186201192579
Unknown or Not Reported298284295877
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSodium Nitrite 45 mgSodium Nitrite 60 mgTotal
White271288273832
Black495851158
Asian383931108
Other35210
Unknown135109140384
Region of Enrollment
Region of Enrollment(participants)PlaceboSodium Nitrite 45 mgSodium Nitrite 60 mgTotal
United States4964994971492
08

Study locations

1 site
  • Harborview Medical Center
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Kim F, Maynard C, Dezfulian C, Sayre M, Kudenchuk P, Rea T, Sampson D, Olsufka M, May S, Nichol G. Effect of Out-of-Hospital Sodium Nitrite on Survival to Hospital Admission After Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021 Jan 12;325(2):138-145. doi: 10.1001/jama.2020.24326. PubMed 33433575 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Dec 2019, 22 months.

Results were first posted in May 2023, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2018
First posted
Mar 2, 2018
StartActual
Feb 8, 2018
Primary completionActual
Dec 31, 2019
CompletionActual
Apr 30, 2020
Results first posted
May 24, 2023
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03452917
Responsible party
Francis Kim (Professor, Medicine/Division of Cardiology, University of Washington) — Principal investigator
First posted
Mar 2, 2018
Start date
Feb 8, 2018
Primary completion
Dec 31, 2019
Completion
Apr 30, 2020
Results posted
May 24, 2023
Last update
May 24, 2023

Study contacts

Francis Kim, MD
principal investigator · University of Washington

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Nitrite

Start the discussion